NAC (N-Acetylcysteine) vs TUDCA
Two supplements with genuine, specific medical pedigrees that get marketed as general 'liver support' and 'antioxidant' pills far beyond what they were proven for.
Short answer
The clearest difference is regulatory. NAC is FDA-approved, and TUDCA is not FDA-approved. NAC is the one to look at if FDA approval matters to you, while TUDCA is marketed for liver health, ER-stress reduction and neuroprotection. On the evidence, both have human clinical data.
NAC (N-Acetylcysteine)
A cysteine/glutathione precursor that is genuinely strong for specific medical uses (acetaminophen-overdose antidote, some psychiatry) but weak as an everyday 'antioxidant/detox' pill.
Full NAC (N-Acetylcysteine) evidence reviewTUDCA
Tauroursodeoxycholic acid
Real bile-acid chaperone biology with genuine human trial engagement — it was the active component of AMX0035/Relyvrio, which showed a positive phase 2 signal in ALS before its confirmatory phase 3 failed and the drug was withdrawn. The liver/ER-stress mechanism is solid; the clinical outcome record is now a cautionary tale, not a green light.
Full TUDCA evidence reviewNAC (N-Acetylcysteine) vs TUDCA: head to head
- FDA status / approved use
NAC (N-Acetylcysteine)
Approved drug as an acetaminophen-overdose antidote and inhaled mucolytic; also widely sold as a supplementTUDCA
Sold as a dietary supplement, not an approved drug; its relative UDCA is an approved medicine- Marketed for
NAC (N-Acetylcysteine)
Antioxidant, detoxTUDCA
Liver health, ER-stress reduction, neuroprotection- Outcome areas
NAC (N-Acetylcysteine)
Liver / detox; Mood / anxiety / stressTUDCA
Liver / detox; Cognitive function / memory- Evidence grade
NAC (N-Acetylcysteine)
Clinical dataTUDCA
Clinical data- How it works
NAC (N-Acetylcysteine)
Supplies cysteine, the limiting building block for the antioxidant glutathioneTUDCA
Chemical chaperone that eases endoplasmic-reticulum stress in cells- Route and dosing
NAC (N-Acetylcysteine)
Oral supplement, commonly 600–1200 mg/day; intravenous in hospital for overdoseTUDCA
Oral capsule- Headline human result
NAC (N-Acetylcysteine)
56% much or very much improved vs 16% on placebo at 12 weeks in a 50-patient trichotillomania RCTTUDCA
About 30% higher liver and muscle insulin sensitivity after four weeks at 1,750 mg/day in a 2010 study of 20 obese adults- Strongest evidence
NAC (N-Acetylcysteine)
Acetaminophen antidote, NEJM 2008NAC (N-Acetylcysteine) evidence reviewPubMed 18635433TUDCA
AMX0035 phase 2/3 ALS trial, NEJM 2020TUDCA evidence reviewPubMed 32877582- Key safety signal
NAC (N-Acetylcysteine)
Generally well tolerated; GI upset most common; IV use can cause anaphylactoid reactionsTUDCA
Small studies suggest it is at least as well tolerated as UDCA; no long-term data- How it is obtained
NAC (N-Acetylcysteine)
Over the counter as a dietary supplementTUDCA
Over the counter as a dietary supplement
| NAC (N-Acetylcysteine) | TUDCA | |
|---|---|---|
| FDA status / approved use | Approved drug as an acetaminophen-overdose antidote and inhaled mucolytic; also widely sold as a supplement | Sold as a dietary supplement, not an approved drug; its relative UDCA is an approved medicine |
| Marketed for | Antioxidant, detox | Liver health, ER-stress reduction, neuroprotection |
| Outcome areas | Liver / detox; Mood / anxiety / stress | Liver / detox; Cognitive function / memory |
| Evidence grade | Clinical data | Clinical data |
| How it works | Supplies cysteine, the limiting building block for the antioxidant glutathione | Chemical chaperone that eases endoplasmic-reticulum stress in cells |
| Route and dosing | Oral supplement, commonly 600–1200 mg/day; intravenous in hospital for overdose | Oral capsule |
| Headline human result | 56% much or very much improved vs 16% on placebo at 12 weeks in a 50-patient trichotillomania RCT | About 30% higher liver and muscle insulin sensitivity after four weeks at 1,750 mg/day in a 2010 study of 20 obese adults |
| Strongest evidence | Acetaminophen antidote, NEJM 2008NAC (N-Acetylcysteine) evidence reviewPubMed 18635433 | AMX0035 phase 2/3 ALS trial, NEJM 2020TUDCA evidence reviewPubMed 32877582 |
| Key safety signal | Generally well tolerated; GI upset most common; IV use can cause anaphylactoid reactions | Small studies suggest it is at least as well tolerated as UDCA; no long-term data |
| How it is obtained | Over the counter as a dietary supplement | Over the counter as a dietary supplement |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
NAC's real strength is narrow and dramatic: it's the antidote for acetaminophen overdose, with genuine psychiatric evidence in some conditions, but weak as an everyday antioxidant. TUDCA's real strength is also narrow: real bile-acid chaperone biology, and it was the active component of a drug that showed a positive Phase 2 signal in ALS before its confirmatory Phase 3 failed and the drug was withdrawn. Both are legitimate molecules with real pedigrees stretched into 'daily liver detox' claims their trials don't support.
NAC (N-Acetylcysteine) fits if
A specific medical use (overdose antidote under supervision, or a psychiatric application discussed with a prescriber) is the actual goal, not general detox.
TUDCA fits if
Liver-specific or ER-stress biology is the interest — but know its highest-profile human outcome trial ultimately failed to confirm.
NAC (N-Acetylcysteine) vs TUDCA: common questions
- Is NAC FDA-approved but TUDCA not?
- Yes. NAC is an approved drug as an acetaminophen-overdose antidote and inhaled mucolytic; also widely sold as a supplement. TUDCA is sold as a dietary supplement, not an approved drug; its relative UDCA is an approved medicine.
- Which has stronger human evidence, NAC or TUDCA?
- Neither clearly. Both have human clinical data. The key source for NAC is Acetaminophen antidote, NEJM 2008; for TUDCA, it is AMX0035 phase 2/3 ALS trial, NEJM 2020.
- What are the main safety concerns with NAC and TUDCA?
- NAC is generally well tolerated; GI upset most common; IV use can cause anaphylactoid reactions. With TUDCA, small studies suggest it is at least as well tolerated as UDCA; no long-term data.
Key studies behind each
NAC (N-Acetylcysteine)
- Heard KJ. (2008). Acetylcysteine for acetaminophen poisoning. N Engl J Med. PubMed 18635433
- Deepmala, Slattery J, Kumar N, et al. (2015). Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev. PubMed 25957927
- Grant JE, Odlaug BL, Kim SW. (2009). N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. PubMed 19581567
- Zheng JP, Wen FQ, Bai CX, et al. (2014). Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. PubMed 24621680
TUDCA
- Poupon RE, Balkau B, Eschwège E, Poupon R; UDCA-PBC Study Group. (1991). A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. PubMed 1674105
- Ozcan U, Yilmaz E, Ozcan L, et al. (2006). Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. PubMed 16931765
- Kars M, Yang L, Gregor MF, et al. (2010). Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. PubMed 20522594
- Paganoni S, Macklin EA, Hendrix S, et al. (2020). Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N Engl J Med. PubMed 32877582
The full evidence reviews
- NAC (N-acetylcysteine): a real antidote, an oversold antioxidant
NAC is the hospital-standard antidote for acetaminophen overdose and has real support in some psychiatry, as a mucolytic and for fertility — but the everyday 'antioxidant / detox / anti-aging' use it's mostly sold for is the weakest part of the story.
Updated August 2026
- TUDCA: real bile-acid biology, an approved parent drug, and a failed flagship trial
TUDCA is a genuine ER-stress-calming chemical chaperone whose parent compound (UDCA/ursodiol) is an approved liver drug — but the longevity and broad supplement claims rest on mechanism and small or animal studies, and its highest-profile human program (ALS / Relyvrio) failed phase 3 and was withdrawn in 2024.
Updated August 2026